Professor, Internal Medicine, TX AandM Univ Coll of Med
Oncology
Dr. Robert G. Mennel, MD
|
|
Give Review
Doctor Robert G. Mennel, MD works in the field of Oncology. He researched medicine at Perelman School of Medicine at the University of Pennsylvania. He has 6 awards "Regional Top Doctor", "Meaningful Use Stage 1 Certification", "Fellow (FASCO)", "Fellow (FACP)", "Super Doctor" and "Top MD". Robert G. Mennel is also a published doctor. He has 35 publication published. The most recent publication is: A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. Doctor Robert G. Mennel, MD is registered with Medicare.
Publications
- Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research...
- Primary effusion Lymphoma diagnosed by pericardiocentesis.
- The ectopic adrenocorticotropic hormone syndrome in carcinoid Tumors.
- Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast Cancer.
- ROBERT GARY MENNEL, MD: a conversation with the editor.
- Phase II study of pemetrexed in patients pretreated with an anthracycline, a taxane, and capecitabine for advanced breast Cancer.
- Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast Cancer.
- Phase I study of oral CI-994 in combination with gemcitabine in treatment of patients with advanced Cancer.
- Adjuvant chemotherapy with doxorubicin and cyclophosphamide in women with rapidly proliferating node-negative breast Cancer.
- ACCO: ASCO core curriculum outline.
- Primary cutaneous angiosarcoma of the Breast after Breast trauma.
- Primary cutaneous large B-Cell lymphoma, leg type.
- Pigmented villonodular synovitis responsive to imatinib therapy.
- American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast Cancer.
- Phase I study of CT-2103, a polymer-conjugated paclitaxel, and carboplatin in patients with advanced solid Tumors.
- A phase II study of piritrexim in patients with advanced squamous head and neck Cancer.
- Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast Cancer.
- Low proliferative rate of invasive node-negative breast Cancer predicts for a favorable outcome: a prospective evaluation of 669 patients.
- Randomized, double-blind, placebo-controlled trial to evaluate the hematopoietic growth factor PIXY321 after moderate-dose fluorouracil, doxorubicin, and cyclophospham...
- A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast Cancer.
- Guidelines for systemic therapy of early stage breast Cancer.
- Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adj...
- Tumor marker utility grading System: a framework to evaluate clinical utility of tumor markers.
- Paclitaxel with mitoxantrone, fluorouracil, and high-dose leucovorin in the treatment of metastatic breast Cancer: a phase II trial.
- Neoadjuvant chemotherapy and liver transplantation for hepatoCellular carcinoma: a pilot study in 20 patients.
- Phase II evaluation of carboplatin and VP-16 for patients with metastatic breast Cancer and only one prior chemotherapy regimen.
- Quantitation by gas chromatography-chemical ionization-mass spectrometry of phenylalanine mustard in plasma of patients.
- The preoperative and operative assessment of aortic regurgitation. Cineaortography vs. electromagnetic flowmeter.
- Phase I trial of adjuvant chemotherapy with cyclophosphamide, epirubicin and 5-fluorouracil (CEF) for stage II breast Cancer.
- Phase II study of mitoxantrone, leucovorin, and infusional fluorouracil for treatment of metastatic breast Cancer.
- Exemestane improves survival in metastatic breast Cancer: results of a phase III randomized study.
- Ocular metastases from breast Cancer.
- 2000 update of recommendations for the use of tumor markers in breast and colorectal Cancer: clinical practice guidelines of the American Society of Clinical Oncology.
- Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast Cancer: results of a phase III randomized double-blind...
Schools
Univ Of Pa Sch Of Med
Strong Meml Hospital Rochester
Johns Hopkins
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Regional Top Doctor
- Meaningful Use Stage 1 Certification
- Fellow (FASCO)
- Fellow (FACP)
- Super Doctor
- Top MD
Education
-
Johns Hopkins University -
University of Rochester -
Perelman School of Medicine at the University of Pennsylvania
Hospital
-
Baylor University Medical Center -
Medical City Dallas Hospital
Drug Facts
| NPI NUMBER | 1265475677 | |
| NPPES Provider LastName | MENNEL | |
| NPPES Provider FirstName | ROBERT | |
| NPPES Provider ZIPCode | 752462003 | |
| NPPES Provider State | TX | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 606.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 50.0 | |
| Percent Opioid Claims | 8.25 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1265475677 |
| Last Name Of The Provider | MENNEL |
| First Name Of The Provider | ROBERT |
| View All |
Similar Doctors
|
|
Dr. Larry D. Anderson Jr., MD |
|
|
Dr. Robert H. Collins Jr., MD |
|
|
Dr. Maria I. Juarez, MD |
|
|
Dr. Claude A. Denham Jr., MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Arve W. Gillette, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mark W. Walberg, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Minal A. Barve, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Andrew R. Whiteley, MD
This Doctor is OpenDoctor Recommended.
|